Tag: William Lee

Gilead Sciences, Second Genome form IBD drug discovery alliance

pharmanewsdaily- April 9, 2020

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More